IBRX Q1 2023 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$360,000+2471.4% YoY

Gross Profit

-$6M-1643.9% margin

Operating Income

-$112M-30994.4% margin

Net Income

-$116M-32317.5% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+393.2%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$93M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$343M

Total Liabilities

$875M

Stockholders' Equity

-$529M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$360,000	$14,000	+2471.4%
Gross Profit	-$6M	-$5M	-9.7%
Operating Income	-$112M	-$96M	-16.3%
Net Income	-$116M	-$103M	-13.1%